GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Mydecine Innovations Group Inc (NEOE:MYCO) » Definitions » Gross-Profit-to-Asset %

Mydecine Innovations Group (NEOE:MYCO) Gross-Profit-to-Asset % : 0.00% (As of Sep. 2023)


View and export this data going back to 2014. Start your Free Trial

What is Mydecine Innovations Group Gross-Profit-to-Asset %?

Gross-Profit-to-Asset % is calculated as Gross Profit divided by its average Total Assets over a certain period of time. Mydecine Innovations Group's annualized Gross Profit for the quarter that ended in Sep. 2023 was C$0.00 Mil. Mydecine Innovations Group's average Total Assets over the quarter that ended in Sep. 2023 was C$2.74 Mil. Therefore, Mydecine Innovations Group's annualized Gross-Profit-to-Asset % for the quarter that ended in Sep. 2023 was 0.00%.


Mydecine Innovations Group Gross-Profit-to-Asset % Historical Data

The historical data trend for Mydecine Innovations Group's Gross-Profit-to-Asset % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Mydecine Innovations Group Gross-Profit-to-Asset % Chart

Mydecine Innovations Group Annual Data
Trend Dec13 Aug14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Gross-Profit-to-Asset %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 4.17 1.61 0.05 0.08 -

Mydecine Innovations Group Quarterly Data
Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23
Gross-Profit-to-Asset % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Mydecine Innovations Group's Gross-Profit-to-Asset %

For the Drug Manufacturers - Specialty & Generic subindustry, Mydecine Innovations Group's Gross-Profit-to-Asset %, along with its competitors' market caps and Gross-Profit-to-Asset % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Mydecine Innovations Group's Gross-Profit-to-Asset % Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Mydecine Innovations Group's Gross-Profit-to-Asset % distribution charts can be found below:

* The bar in red indicates where Mydecine Innovations Group's Gross-Profit-to-Asset % falls into.



Mydecine Innovations Group Gross-Profit-to-Asset % Calculation

Mydecine Innovations Group's annualized Gross-Profit-to-Asset % for the fiscal year that ended in Dec. 2022 is calculated as:

Gross-Profit-to-Asset %=Gross Profit (A: Dec. 2022 )/( (Total Assets (A: Dec. 2021 )+Total Assets (A: Dec. 2022 ))/ count )
=0/( (7.581+6.901)/ 2 )
=0/7.241
=0.00 %

Mydecine Innovations Group's annualized Gross-Profit-to-Asset % for the quarter that ended in Sep. 2023 is calculated as:

Gross-Profit-to-Asset %=Gross Profit (Q: Sep. 2023 )/( (Total Assets (Q: Jun. 2023 )+Total Assets (Q: Sep. 2023 ))/ count )
=0/( (1.025+4.454)/ 2 )
=0/2.7395
=0.00 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Gross-Profit-to-Asset %, the Gross Profit of the last fiscal year and the average total assets over the fiscal year are used. In calculating the quarterly data, the Gross Profit data used here is four times the quarterly (Sep. 2023) data. Gross-Profit-to-Asset % is displayed in the 30-year financial page.


Mydecine Innovations Group Gross-Profit-to-Asset % Related Terms

Thank you for viewing the detailed overview of Mydecine Innovations Group's Gross-Profit-to-Asset % provided by GuruFocus.com. Please click on the following links to see related term pages.


Mydecine Innovations Group (NEOE:MYCO) Business Description

Traded in Other Exchanges
Address
789 West Pender Street, Suite 810, Vancouver, BC, CAN, V6C 1H2
Mydecine Innovations Group Inc is a biopharma and life sciences company engaged in the research, drug development, and clinical trials of psilocybin products.

Mydecine Innovations Group (NEOE:MYCO) Headlines

No Headlines